RVNC Stock Recent News
RVNC LATEST HEADLINES
NASHVILLE, Tenn., May 27, 2025 /PRNewswire/ -- Revance is proud to announce that Blue Lizard® Australian Sunscreen, the #1 best-selling mineral SPF brand in the U.S.*, is celebrating National Sunscreen Day on May 27th with a dynamic digital billboard in New York City's Times Square, capping off Skin Cancer Awareness Month and heading into sun season with a bold message: Be Fearless in the Sun. "We're excited to mark National Sunscreen Day in such a powerful way," said Steve Gallopo, Executive Vice President and Chief Commercial Officer, Consumer Skincare. "This billboard is a monumental celebration of our heritage in mineral sun protection and a call to action for everyone to take sun safety seriously." "Our mission is to make sun protection accessible and easy for the whole family," added Nicole Watson, SVP Global Therapeutics Marketing, Consumer Skincare. "This recent rebrand reflects that, with cleaner formulas, enhanced aesthetics, and the same uncompromising SPF 50 protection peo
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Revance Therapeutics, Inc. (NASDAQ:RVNC) on behalf of long-term stockholders following a class action complaint that was filed against Revance on January 3, 2025 with a Class Period from February 29, 2024 to December 6, 2024. Our investigation concerns whether the board of directors of Revance have breached their fiduciary duties to the company.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133949&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133907&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Revance Therapeutics, Inc. (NASDAQ:RVNC) between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), of the important March 4, 2025 lead plaintiff deadline. SO WHAT: If you purchased Revance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133865&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133817&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
NEW YORK , March 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024.